JAK2 and myeloproliferative disorder: A small minority of ET and PMF patients fall into the “triple negative” category with no detectable mutation in JAK2, MPL or CALR. The incorporation of additional genetic tests into the work-up of these patients has challenged the notion of true triple negativity in MPN.